Jefferson Buntin
Primary Care · Picayune, MSNPI 1114318417
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations.
Across 135 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$598
- Novartis$296
- AstraZeneca$230
- Lilly USA, LLC$192
- Xeris Pharmaceuticals, Inc.$153
- Novo Nordisk$128
- plus $901 from 22 others
What the payments were for
- Food & beverage$2,46999%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $598 |
| Novartis | 13 | $296 |
| AstraZeneca | 8 | $230 |
| Lilly USA, LLC | 11 | $192 |
| Xeris Pharmaceuticals, Inc. | 7 | $153 |
| Novo Nordisk | 7 | $128 |
| Corcept Therapeutics | 3 | $83 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $73 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Exact Sciences | 4 | $70 |
| Abbott | 4 | $68 |
| Boehringer Ingelheim | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Merck | 2 | $49 |
| Amgen | 3 | $45 |
| Amarin Pharma, Inc. | 2 | $40 |
| GSK | 2 | $34 |
| Agile Therapeutics, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Bayer | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,499 in reported general payments places this provider in the 80th percentile of 80 primary care providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 135 | $136,284 |
| JardianceEmpagliflozin | 64 | $84,232 |
| EliquisApixaban | 59 | $66,517 |
| XareltoRivaroxaban | 41 | $53,032 |
| TrulicityDulaglutide | 41 | $38,801 |
| JanuviaSitagliptin Phosphate | 29 | $33,586 |
| TradjentaLinagliptin | 30 | $29,167 |
| Spiriva HandihalerTiotropium Bromide | 25 | $25,154 |
| FarxigaDapagliflozin Propanediol | 23 | $24,135 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $21,399 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $18,706 |
| LinzessLinaclotide | 19 | $17,958 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $17,377 |
| MounjaroTirzepatide | 13 | $15,279 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $128 | $136,284135 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Trijardy Xr | $67 | $135,864118 claims |
| PfizerEliquis, Premarin | $17 | $74,13378 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $230 | $60,21898 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $192 | $54,08054 claims |
| MerckJanuvia, Belsomra | $49 | $39,50543 claims |
| AbbVieLinzess, Synthroid | $598 | $21,33656 claims |
| GSKBreo Ellipta | $34 | $15,03432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 80 primary care providers in Mississippi.
Other primary care in Picayune
- Tiffany LeePicayune$205
- Alisha McArthur WilkesRidgeland$17K
- Katrina BlackardSouthaven$14K
- Sarah HarringtonTupelo$11K
- Julie HarperNewhebron$10K
- Hannah IvisonJackson$10K
- Irene WilsonSouthaven$4K
- Mary EatonTupelo$4K
- Tanya SandersonTupelo$3K
- Amanda EllisKosciusko$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.